Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in GFAP

Sunday, July 27, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The SHINE Phase 2 trial presented findings on the plasma proteomic analysis of a biomarker-defined subpopulation. The study aimed to identify molecular correlates associated with a favorable decrease in the neuroinflammatory marker GFAP in Alzheimer's disease participants treated with Zervimesine. These results were shared at the 2025 Alzheimer’s Association International Conference in Toronto.
Price reaction · baseline $0.84 (2025-07-25 close) · 6 other CGTX headline(s) in the window, move may be shared
day 0 close
-14.9%
day 1
-20.2%
day 3 · peak
-30.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Identification of molecular correlates to treatment effectiveness.
  • Favorable decrease in GFAP observed in participants.
  • Focus on biomarker-defined subpopulations enhances precision medicine.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Lizama BN, DiCaro V, Cho E, et al. Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in the Neuroinflammatory Marker GFAP with Zervimesine in Alzheimer’s Disease Participants . Poster presented at 2025 Alzheimer’s Association International Conference (AAIC) ; Toronto, Ontario, Canada

Frequently Asked Questions

What was the focus of the SHINE Phase 2 trial?

The trial focused on plasma proteomic analysis in a biomarker-defined subpopulation.

What marker showed a favorable decrease in the trial?

The neuroinflammatory marker GFAP showed a favorable decrease.

Where were the findings of the trial presented?

The findings were presented at the 2025 Alzheimer’s Association International Conference.

What treatment was used in the SHINE trial?

Participants were treated with Zervimesine during the trial.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare Zervimesine Alzheimer's disease GFAP biomarker plasma proteomics
Last updated: Jul 27, 2025

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →